Trial Profile
A Single-center, Prospective, Non-randomized Study of Factor Xa inhibition by Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Sep 2017
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism and thrombosis
- Focus Pharmacokinetics
- 15 Sep 2017 New trial record
- 09 Sep 2017 Results published in the British Journal of Clinical Pharmacology